Literature DB >> 19161158

Use of antihistamine medications during early pregnancy and isolated major malformations.

Suzanne M Gilboa1, Matthew J Strickland, Andrew F Olshan, Martha M Werler, Adolfo Correa.   

Abstract

BACKGROUND: Antihistamines are commonly used during pregnancy. There is little evidence that they have teratogenic effects, but there are knowledge gaps with respect to newer products, as well as the relationship between specific antihistamines and specific birth defects.
METHODS: Using the National Birth Defects Prevention Study (1997-2003), the authors examined associations between maternal use of 14 antihistamines during early pregnancy and 26 isolated major birth defects. A Bayesian analysis incorporating prior knowledge about the relationships between antihistamines, birth defects, and measured covariates was conducted.
RESULTS: Of the 364 associations investigated, 24 had 95% posterior intervals excluding 1.0. All 24 associations were positive; 23 associations were of weak to moderate magnitude (posterior OR < 3.0) and one was strong (OR > 6.0) but very imprecise. Of the 24 associations, 20 were with noncardiac defects. Eight associations involved the antihistamine diphenhydramine.
CONCLUSIONS: The results of this study generally were consistent with no association between birth defects and antihistamine use during early pregnancy. Several of the findings might warrant further investigation, although the observed elevated associations should be interpreted in the context of the number of associations investigated and the analysis of retrospective, self-reported data. (c) 2009 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19161158      PMCID: PMC3619228          DOI: 10.1002/bdra.20513

Source DB:  PubMed          Journal:  Birth Defects Res A Clin Mol Teratol        ISSN: 1542-0752


  40 in total

1.  Further evidence that histamine H1-antagonists cause joint weakness in rat foetuses.

Authors:  G Sturman; P Freeman; H M Meade; N A Seeley
Journal:  Inflamm Res       Date:  2002-04       Impact factor: 4.575

2.  Bendectin and birth defects: hopefully, the final chapter.

Authors:  Robert Brent
Journal:  Birth Defects Res A Clin Mol Teratol       Date:  2003-02

3.  Pregnancy outcome following first trimester exposure to antihistamines: meta-analysis.

Authors:  A Seto; T Einarson; G Koren
Journal:  Am J Perinatol       Date:  1997-03       Impact factor: 1.862

4.  Seeking causes: Classifying and evaluating congenital heart defects in etiologic studies.

Authors:  Lorenzo D Botto; Angela E Lin; Tiffany Riehle-Colarusso; Sadia Malik; Adolfo Correa
Journal:  Birth Defects Res A Clin Mol Teratol       Date:  2007-10

5.  Use of antihistamine drugs in early pregnancy and delivery outcome.

Authors:  B Källén
Journal:  J Matern Fetal Neonatal Med       Date:  2002-03

6.  Bendectin and birth defects: I. A meta-analysis of the epidemiologic studies.

Authors:  P M McKeigue; S H Lamm; S Linn; J S Kutcher
Journal:  Teratology       Date:  1994-07

7.  Monitoring for new multiple congenital anomalies in the search for human teratogens.

Authors:  M J Khoury; L Botto; G D Waters; P Mastroiacovo; E Castilla; J D Erickson
Journal:  Am J Med Genet       Date:  1993-06-01

8.  Bendectin (Debendox) as a risk factor for pyloric stenosis.

Authors:  B Eskenazi; M B Bracken
Journal:  Am J Obstet Gynecol       Date:  1982-12-15       Impact factor: 8.661

9.  Bendectin and human congenital malformations.

Authors:  P H Shiono; M A Klebanoff
Journal:  Teratology       Date:  1989-08

10.  Birth defects in relation to Bendectin use in pregnancy. II. Pyloric stenosis.

Authors:  A A Mitchell; P J Schwingl; L Rosenberg; C Louik; S Shapiro
Journal:  Am J Obstet Gynecol       Date:  1983-12-01       Impact factor: 8.661

View more
  22 in total

Review 1.  [Allergic diseases in pregnancy. Overview of diagnosis and therapy].

Authors:  R Treudler
Journal:  Hautarzt       Date:  2010-12       Impact factor: 0.751

2.  Pregnancy and skin.

Authors:  Sumit Kar; Ajay Krishnan; Poonam Varma Shivkumar
Journal:  J Obstet Gynaecol India       Date:  2012-08-28

3.  The safety or risk of antihistamine use in pregnancy: reassuring data are helpful but not sufficient.

Authors:  Margaret A Honein; Cynthia A Moore
Journal:  J Allergy Clin Immunol Pract       Date:  2013-10-31

4.  Assessment of antihistamine use in early pregnancy and birth defects.

Authors:  Qian Li; Allen A Mitchell; Martha M Werler; Wai-Ping Yau; Sonia Hernández-Díaz
Journal:  J Allergy Clin Immunol Pract       Date:  2013-09-12

Review 5.  The Risk of Adverse Pregnancy Outcome After First Trimester Exposure to H1 Antihistamines: A Systematic Review and Meta-Analysis.

Authors:  Fatma Etwel; Lauren H Faught; Michael J Rieder; Gideon Koren
Journal:  Drug Saf       Date:  2017-02       Impact factor: 5.606

6.  Medications used to treat nausea and vomiting of pregnancy and the risk of selected birth defects.

Authors:  Marlene Anderka; Allen A Mitchell; Carol Louik; Martha M Werler; Sonia Hernández-Diaz; Sonja A Rasmussen
Journal:  Birth Defects Res A Clin Mol Teratol       Date:  2011-11-19

7.  Maternal medication and herbal use and risk for hypospadias: data from the National Birth Defects Prevention Study, 1997-2007.

Authors:  Jennifer N Lind; Sarah C Tinker; Cheryl S Broussard; Jennita Reefhuis; Suzan L Carmichael; Margaret A Honein; Richard S Olney; Samantha E Parker; Martha M Werler
Journal:  Pharmacoepidemiol Drug Saf       Date:  2013-04-26       Impact factor: 2.890

8.  Safety of antihistamines during pregnancy and lactation.

Authors:  Miranda So; Pina Bozzo; Miho Inoue; Adrienne Einarson
Journal:  Can Fam Physician       Date:  2010-05       Impact factor: 3.275

9.  Challenges in Studying Modifiable Risk Factors for Birth Defects.

Authors:  Sarah C Tinker; Suzanne Gilboa; Jennita Reefhuis; Mary M Jenkins; Marcy Schaeffer; Cynthia A Moore
Journal:  Curr Epidemiol Rep       Date:  2015-03

10.  Early pregnancy exposure to antihistamines and risk of congenital heart defects: results of two case-control studies.

Authors:  Huberdina P M Smedts; Linda de Jonge; Sarah J G Bandola; Marlies E Baardman; Marian K Bakker; Bruno H C Stricker; Régine P M Steegers-Theunissen
Journal:  Eur J Epidemiol       Date:  2014-06-20       Impact factor: 8.082

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.